|
|
Phase III Randomized Study of Naproxen in Preventing Pegfilgrastim-Induced Bone Pain in Patients With Non-Hematologic Malignancies Undergoing Chemotherapy
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Naproxen in Preventing Bone Pain Caused by Pegfilgrastim in Patients With Non-Hematologic Cancer Undergoing Chemotherapy
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Supportive care
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
URCC-07079 URCC07079, URCC-06-06, NCT00602420
|
|
|
Objectives Primary - To compare the efficacy of daily administration of naproxen vs placebo in preventing or reducing the severity and duration of pegfilgrastim-induced bone pain (PIBP) in patients with non-hematologic malignancies undergoing chemotherapy.
Secondary - To identify potential risk factors for the development of PIBP.
- To identify potential clinical predictors for the response or failure to respond to
naproxen in preventing PIBP.
- To assess the toxicity of naproxen when administered in
the preventive setting.
Entry Criteria Disease Characteristics:
- Diagnosis of a non-hematologic (non-myeloid) malignancy
- Scheduled to
receive chemotherapy
- Chemotherapy may be given for adjuvant, neoadjuvant, curative, or palliative intent
- Scheduled to receive the first dose of pegfilgrastim (Neulasta®) to ameliorate chemotherapy-induced
neutropenia
Prior/Concurrent Therapy:
- See Disease Characteristics
- More than 6 months since prior surgery on the heart
- No concurrent nonsteroidal anti-inflammatory
drugs (NSAIDs), such as aspirin, ibuprofen, or any product containing naproxen (e.g., Naprosyn, EC-Naprosyn, Anaprox, Anaprox-DS, Naprosyn
suspension, or Aleve), on a regular basis
- No concurrent steroids on a regular basis
- No concurrent prescription or non-prescription medications for preexisting
chronic pain
- Concurrent cardioprotective doses (≤ 325 mg/day) of aspirin allowed
- No concurrent therapeutic doses of warfarin
Patient Characteristics:
- Not pregnant or nursing
- Creatinine ≤ 1.5 times upper limit of normal
- Able to understand English
- No clinical evidence of active gastrointestinal bleeding, prior gastrointestinal bleeding, or gastric or duodenal ulcers
- No known allergy to naproxen
- No prior development of the triad of asthma,
rhinitis, and nasal polyps after taking acetylsalicylic acid (aspirin) or other NSAIDs
Expected Enrollment 322Outcomes Primary Outcome(s)Severity and duration of bone pain from baseline through day 5 (day 1 being the day pegfilgrastim is administered) as measured by a daily diary
Secondary Outcome(s)Potential risk factors for the development of pegfilgrastim-induced bone pain Potential clinical predictors for response or failure to
respond to treatment Presence or severity of symptoms prior to study enrollment and at
study outcome as measured by the Symptom Inventory Toxicity
Outline This is a multicenter study. Patients are stratified by CCOP site. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is
administered (day 2, 3, or 4) and continuing for 5-8 days.
- Arm II: Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing
for 5-8 days.
Patients complete questionnaires, including the Symptom Inventory and Brief Pain Inventory, at baseline and after completion of study treatment. Patients also complete a daily pain diary during study treatment.
Trial Contact Information
Trial Lead Organizations University of Rochester Cancer Center CCOP Research Base | | | Jeffrey Kirshner, MD, Protocol chair | | | | Gary Morrow, PhD, MS, Protocol co-chair | | | | Jeffrey Giguere, MD, FACP, Protocol co-chair | | | | Trial Sites
|
|
|
|
U.S.A. |
|
New York |
|
|
Rochester |
|
| | | | | | | | University of Rochester Cancer Center CCOP Research Base |
| | Gary Morrow, PhD, MS | |
|
|
Syracuse |
|
| | CCOP - Hematology-Oncology Associates of Central New York |
| | Jeffrey Kirshner, MD | |
|
South Carolina |
|
|
Greenville |
|
| | | CCOP - Greenville |
| | Jeffrey Giguere, MD, FACP | |
| Email:
Jeffrey.Giguere@usoncology.com |
|
Registry Information | | Official Title | | Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial | | Trial Start Date | | 2008-06-10 | | Trial Completion Date | | 2011-07-01 (estimated) | | Registered in ClinicalTrials.gov | | NCT00602420 | | Date Submitted to PDQ | | 2008-01-08 | | Information Last Verified | | 2008-08-12 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|